Humatrope | Know The Facts

Share This Story, Choose Your Platform!

What You Need to Know About Humatrope

People who know something about human growth hormones may know something about what is Humatrope and Buy Humatrope. It is recombinant DNA origin of a polypeptide hormone. It has residues of 191 amino acid amino sequence that is like HGH naturally produced by the body. It is produced through a synthesis in a strain of E. coli which has been changed with the addition of a gene for HGH.  

Humatrope is sterile, a freeze-dried powder made to be used subcutaneously or administration via intramuscular after it is reconstituted. It is purified preparation which has sodium hydroxide or phosphoric acid added in order to correct the pH. The reconstituted solution has a pH level of 7.5 and it is important to remember that it is sensitive to oxygen.

Humatrope is sold in vials and each vial contains 5mg Somatropin; 5mg Glycine; 25mg Mannitol; and 1.13mg Dibasic Sodium Phosphate. Each of the vials comes with a diluting solution of 5ml. The diluent has water for injection with preservative.

Cartridges can contain 6mg, 12mg or 24mg of Somatropin. Supplied in a package, each of the cartridges comes with a syringe that has an approximately 3ml diluting solution. The diluent contains water, preservative, and glycerin.

Clinical Pharmacology

Humatrope has a lot of benefits to offer. It stimulates growth in children who do not have enough growth hormones in the body. Clinical and pre-clinical, as well as in-vitro testing has shown that it is tantamount to HGH produced naturally by the body through the pituitary gland and it has similar pharmacokinetic effects in adults.

Humatrope was found to effectively treat pediatric patients who had growth hormone deficiency and Turner Syndrome. Humatrope increased their rate and growth and Insulin-like Growth Factor-I concentrations.

Skeletal growth

By stimulating skeletal growth Humatrope helps children suffering from GHD and it also produced measurable improvement in the length of their bodies by affecting the plates of long bones growth. It has long been believed that IGF-I impacts skeletal growth and it seems there is a truth to this.

Pediatric patients who suffer from GHD have typically lower concentrations of IGF-I and HGH therapy with Humatrope has helped increased IGF-I concentrations. It also elevated serum alkaline phosphate concentrations.

Cell growth

Humatrope has been found to increase the size and number of muscle cells. Children who lack natural growth hormones have short statures because they typically have fewer skeletal muscle cells.

Metabolism of Carbohydrates

Children who suffer from hypopituitarism sometimes develop fasting hypoglycemia or low blood sugar levels. Humatrope improves this condition. However, large doses may affect glucose tolerance. Patients suffering from Turner syndrome when left untreated have higher rates of glucose intolerance. Treatment with HGH therapy has increased patients’ fasting of mean serum, as well as postprandial levels of insulin.

Metabolism of Lipids

Patients who suffer from GHD who are treated with HGH of pituitary origins have been found to have better lipid mobilization, increased fatty acids, and reduced body fat.

Protein Metabolism

Improved cellular protein synthesis helps improve linear growth and Humatrope improves nitrogen retention and decreases serum urea nitrogen.

Mineral Metabolism

HGH induces retention of phosphorous, potassium and sodium. Patients who suffer from GHD who has been treated with Humatrope turned out to have better serum concentrations of phosphate that are inorganic while there was no significant change found in serum calcium.


Humatrope can be administered in different ways in patients and each has been studied carefully. Somatropin has a total bioavailability of 63% and 75% after subcutaneous and metabolism.

There have not been many studies conducted on HGH metabolism. Somatropin has the typical protein catabolism in the kidneys and the liver. Some breakdown products of GH are returned to systematic circulation in renal cells. There was a mean clearance 0.14 L/hr/kg in normal volunteers. Intravenous Somatropin has a half-life of 0.36 hours while subcutaneous and intramuscular Somatropin have half-lives of 3.8-4.9 hours. The longer half-life is attributed to its slower absorption.

There has been no measurement yet of the urinary elimination of whole Humatrope. However, a small amount of somatropin has been identified in the urine of young patients after HGH replacement treatment.

Particular Populations

Humatrope pharmacokinetics studies do not include patients over 60 years old. However, the Humatrope pharmacokinetics in children is similar to that of adults. No Humatrope studies have been done on gender. What the available literature shows is that it is similar to both women and men. There is no data available for race, renal and hepatic insufficiency.

HGH Indications and Usage

Humatrope can be used for long-term treatment of children who have growth failure problems due to insufficient secretion of normal growth hormones. It is also indicated for the treatment of short stature caused by Turner syndrome whose epiphyses are not closed.

HGH Contraindications

Humatrope must not be used if there is any malignancy indication. Treatment of Anti-malignancy should be finished with signs of remission before administering HGH treatment. Humatrope must not be used with the accompanying diluent by people who have sensitivity to glycerin or Melacresol.

Patients who have acute illnesses caused by open heart surgery, multiple trauma, and acute respiratory failure must not be started on HGH therapy. An increased mortality rate was found by a study among people with the aforementioned health problems who were treated with Somatropin.